Dr. Michael L. Cher, MD

Dr. Cher practices at Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care.

Dr. Cher's NPI, 1336187400, was assigned on June 2, 2006. Dr. Cher graduated from WashU Medicine in 1986. Dr. Cher holds Michigan license 4301065742.

Dr. Cher's primary practice is Karmanos Cancer Center, at 4100 John R, Detroit, MI 48201 in Wayne County. The practice phone is (800) 576-6266.

Dr. Cher's primary practice is Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care. Dr. Cher is also affiliated with DMC Harper University Hospital. The medical group on file is Wayne Health. Dmand AI also links Dr. Cher to 3 more hospitals, 1 physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cher practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Cher's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Cher is board certified in urology by the American Board of Urology. Dmand AI has Dr. Cher's licenses on file in 3 states: Michigan, California and Texas.

Dmand AI lists bladder disease, bladder removal, enlarged prostate, erectile dysfunction, kidney cysts, kidney removal surgery, prostate cancer and prostate surgery among the conditions Dr. Cher treats.

CMS data shows 302 Medicare services from Dr. Cher across 6 procedure codes in 2024, for 225 Medicare patients. Medicare paid $19,170 for them.

CMS counts 225 Medicare patients who saw Dr. Cher in 2024. The largest group is 65 to 74, with 106 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cher's median patient age at 71, with 18% women.

In 2024, Dr. Cher wrote 360 Medicare Part D claims for 118 patients. 89% of them were for generic drugs. CMS names the drug for 300 of them, across 10 drugs with 11 or more claims each, at $421,694 in total drug cost. In 2023, CMS named 272 claims across 7 drugs.

Dr. Cher accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cher as offering telehealth. CMS counts 20 procedures of prostate resection by Dr. Cher, more than 81% of the clinicians it reports for that procedure.

Dmand AI links 134 papers to Dr. Cher, published from 2003 to 2024. 2017 was the busiest year, with 9. The most frequent topics are Prostatic Neoplasms, Bone Neoplasms and Prostatectomy. Dr. Cher has published most often in J Urol. Dr. Cher's most frequent co-authors are Wael Assad Sakr, MD, Khurshid Ridwan Ghani, MD and Peter R. Carroll, MD.

Dmand AI links Dr. Cher to 4 clinical trials. 3 are still active or recruiting. Conditions studied include Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Renal Cell and Prostatic Neoplasms. ImmunityBio, Inc. sponsors the most, 2.

CMS Open Payments shows 159 general payments to Dr. Cher from 32 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 45% of the total. Merck Sharp & Dohme Corporation paid the most, $4,689.

Dmand AI lists 3 awards for Dr. Cher, most recently Hour Magazine Top Doc in 2019.

Dr. Cher graduated from WashU Medicine in 1986.

Dr. Cher is in network with 19 carriers, including Aetna, Elevance and Health Alliance Plan. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.